INTRODUCTION AND OBJECTIVES:
With the recognition that limiting opiate exposure mitigates long term dependency, efforts have been taken to critically assess perioperative narcotic use. Eight years ago we completed a prospective, randomized study that demonstrated improved post-operative pain control in patients who received a belladonna and opium suppository (BNO) upon anesthesia induction prior to roboticassisted laparoscopic prostatectomy (Lukasewycz et al. Can J Urol 2010; 17:5377-82) . Contemporarily, there are significant efforts to limit perioperative opiates, due to concerns that even limited use may contribute to long-term abuse. In the present study, we recontact our initial study participants to assess whether the perioperative exposure to opiates was associated with significant long-term narcotic use.
METHODS: After Institutional Review Board approval, up to 3 attempts were made to contact each of the 99 patients from the initial study. After consent, a research nurse independent of the original study asked patients to complete a phone survey regarding current pain levels, analgesic use and any other prostate cancer treatments. The International Index of Erectile Function (IIEFF) and the American Urological Association Symptom Score (AUASS) were also administered.
RESULTS: 59/99 original patients (59.6%) were reached and agreed to participate. Of these, 45 (76.3%) reported no current pain and 14 (23.7%) reported current musculoskeletal pain unrelated to their prostatectomy ( Fig. 1) . Of the patients who experience daily pain, 12/14 (85.7%) managed their discomfort without opiates; 2 reported current opiate use (oxycodone and tramadol). 1 of these patients was originally randomized to the BNO cohort while the other was in the non-BNO group. There were no statistical differences in IIEF, current protective pad usage or AUASS comparing patients reporting pain with patients reporting no pain.
CONCLUSIONS: In this 8-year post-operative follow-up study, 2/59 (3.4%) of patients report narcotic use for chronic pain not associated with their prostatectomy. This suggests that while perioperative narcotics may be used judiciously, a multimodal approach should be considered. Within our population, short-term narcotic exposure did not induce long-term dependency. ROCKS maintains an all-payer clinical registry in which detailed patient and perioperative information is prospectively captured for patients undergoing URS at a participating practice in Michigan. We abstracted registry data on and calculated practice-level use of postoperative opiates, non-steroidal anti-inflammatory drugs (NSAIDs), and alpha blockers. We supplemented these data with a 15-item survey that was administered to MUSIC ROCKS 0 urologists regarding their postoperative pain management strategies (response rate, 67%).
RESULTS: Data were available on 5,600 URS procedures performed across 34 participating practices between June, 2016 and September, 2018. 85 .9% of these patients received an opiate prescription as part of their postoperative pain management, 85.1% were managed with an opiate alone. For only 11.5% of patients was an NSAID included in the postoperative pain regimen. In contrast, 46.6% of survey respondents indicated that they prescribed an NSAID after a majority of their cases. Registry data revealed that 55.1% and of patients were prescribed alpha blockers postoperatively. This rate varied substantially between practices ( Figure: range 0% -100%, P[<0.01), and only 18.7% of survey respondents prescribed anticholinergics in a majority of their patients.
CONCLUSIONS: There is substantial variability in urologists 0 approach to pain management after URS across Michigan. Our analysis highlights low use of NSAIDs, alpha blockers, and anticholinergics, suggesting opportunities for improvement.
